AstraZeneca Reports Significant Proteinuria Reduction With Ultomiris In Rare Kidney Disease - AstraZeneca

AstraZeneca's Ultomiris cut proteinuria by 46.6% in Phase 3 IgAN trial interim analysis, supporting regulatory filings.

Raccontata dabenzinga.com